MDT
★★★☆☆ WatchtemplateMedtronic plc
Healthcare · sector percentile 100
세션 움직임
$87.09
거래량 2.92× 평균
73/100 quant · tgt $104.83
RS60 +0.2% vs SPY · ADV$ 1579.1M
세션 2026-10-06 · 스냅샷 — 실시간 호가 아님
직전 스캔 대비
2026-10-06 → 2026-10-07
참고용이며 매수/매도 신호가 아닙니다. 스캔 이력과 캐시된 뉴스·공시로 구성됩니다.
스냅샷 시세
세션 2026-10-06 · 스캔 2026-10-07 · 푸시 10-07 13:12 ET · 정규장 (오래됨)
시세 상세 보기시세 상세 숨기기
- 종가/스캔가
- $87.27
- 전일 종가
- $87.97
- 푸시 최신가
- $86.75 (오래됨) · 10-07 13:12 ET · 정규장
- 세션 시가
- $87.97
- 직전 세션 범위
- $86.45 – $88.50
- 52주 범위
- $72.65 – $103.76
- 세션 거래량
- 52,132,703
- 평균 거래량 (20일)
- 17,825,020
- 시가총액
- $111.63B
- PER (TTM)
- 21.44
- Forward PER
- 13.61
- 배당 수익률
- 3.27%
- 1년 목표가 추정
- $104.83
- 다음 실적
- 2026-11-17
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes.
$1,000.00 넣었다면 지금
1년 전
$907.60
−9%
5년 전
$809.14
−19%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
시장 브리핑
선별된 요약입니다 — 매매 신호가 아닙니다. 헤드라인·링크는 제공된 그대로 표시됩니다.
- Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive
Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.
Yahoo · 2026-10-01
- Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. T
Yahoo · 2026-10-01
- Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
Yahoo · 2026-09-30
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — MDT scores 73.15/100 (Watch) with revenue growth at 13.7% and a multi-factor profile supporting the current ranking.
- Risks — Key risks for MDT include valuation compression, sector rotation, and any deterioration in earnings momentum or balance-sheet leverage. Context: cached next earnings 2026-11-17.
- Target Upside — Consensus implied upside is 20.1%. Category 'Watch' suggests monitoring position sizing against the 100-point model thresholds.
Score History
30 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-10-07$87.27−$1.2173.2Watch
- 2026-10-06$88.48+$2.1074.0Watch
- 2026-10-05$86.38+$0.3669.4Pass
- 2026-10-02$86.02+$0.0972.3Watch
- 2026-10-01$85.93−$0.4772.0Watch
- 2026-09-30$86.41−$1.3474.4Watch
- 2026-09-29$87.75−$0.2175.6Watch
- 2026-09-28$87.96+$0.3174.0Watch
- 2026-09-25$87.65−$1.6573.6Watch
- 2026-09-24$89.30−$1.4773.7Watch
- 2026-09-23$90.77−$0.9869.2Pass
- 2026-09-22$91.75−$0.2368.9Pass
- 2026-09-21$91.98−$0.2676.2Watch
- 2026-09-18$92.24−$0.7676.4Watch
- 2026-09-17$93.00−$0.9277.2Watch
- 2026-09-16$93.93+$0.5675.4Watch
- 2026-09-15$93.37−$0.1775.8Watch
- 2026-09-14$93.53+$2.1275.9Watch
- 2026-09-11$91.41−$0.5075.4Watch
- 2026-09-10$91.91−$1.2575.7Watch
- 2026-09-09$93.16−$1.0174.8Watch
- 2026-09-08$94.17$0.0075.3Watch
- 2026-09-07$94.17+$1.0775.3Watch
- 2026-09-04$93.10+$0.9268.7Pass
- 2026-09-03$92.18+$0.1470.9Watch
- 2026-09-02$92.04+$1.3962.8Pass
- 2026-09-01$90.65−$0.5864.0Pass
- 2026-08-31$91.23+$1.2663.9Pass
- 2026-08-28$89.97−$2.0563.8Pass
- 2026-08-27$92.02—63.1Pass
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 71.2%
- vs 20d (z)
- 1.75
- Short vol
- 13,093,691
- Status
- ok
Squeeze pressure score
full63/100
- Short leg
- 68
- Call leg
- 70
- Activity
- 10.0
- Call vol share
- 62.0%
- PCR (vol)
- 0.61
- Call OI share
- 68.1%
- ATM IV
- 48.3%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
공시 점수 (Disclosure)
캐시된 SEC 공시 기반 News / Insider / Earnings 규칙 다리 — 참고용이며, beat/miss나 매수 신호가 아닙니다.
점수 창에 최근 SEC 공시·실적 일정 입력이 아직 없습니다.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
실적 서프라이즈 (퀀트 맥락)
최근 퀀트 스캔에 캐시된 Yahoo/공개 펀더멘털 수치입니다 — 공시 이벤트 점수에 합산되지 않으며 매수 신호가 아닙니다. 최신 발표보다 늦을 수 있습니다.
최근 보고 서프라이즈 +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-11-17yahoo_calendar
- Last earnings
- 2026-09-01yahoo_calendar
- SEC ↗8-K2026-09-17
8-K
- SEC ↗42026-09-17
FORM 4
- SEC ↗42026-09-16
FORM 4
- SEC ↗10-Q2026-09-03
10-Q
- SEC ↗8-K2026-09-01
8-K
- SEC ↗42026-08-24
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.